Canaccord Reiterates Buy Rating on Natera (NTRA) following Q4

Canaccord analyst Kyle Mikson reiterated a Buy rating and $285.00 price target on Natera (NASDAQ: NTRA)

The analyst commented, "We reiterate our BUY rating on Natera (NTRA) shares and maintain our price target at $285. We remain bullish on NTRA (one of our 2026 focus names) and its multifaceted business model following another strong quarter of financial performance. After the market close on Thursday, February 26, the company reported strong 4Q25 results that were ahead of its preannouncement. The company's performance was primarily driven by solid increases in test volume across Natera's three business segments (particularly Signatera [record sequential clinical test volume growth]). The company provided 2026 revenue guidance that reflects pro forma y/y growth in the mid-20% range (as well as strong gross margins and positive cash flow), while increasing R&D meaningfully to support new launches and guideline-driven adoption. With many catalysts across oncology (e.g., Medicare submissions, AI-enabled efficiencies) and Women's Health initiatives (expanded 21-gene Fetal Focus test), we view full-year guidance as conservative, with meaningful upside potential to current estimates."

For an analyst ratings summary and ratings history on Natera click here. For more ratings news on Natera click here.

Shares of Natera closed at $208.04 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Boeing lands two U.S. defense contracts worth over $711M